Emerging evidence links elevated VSIG4 expression to poorer clinical outcomes across multiple solid tumours (e.g., glioma, gastric, breast, lung, pancreatic), positioning this checkpoint protein as a crucial modulator of tumour progression.25, 26, 27, 28. Here, VSIG4 is linked to neoplasm.